Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Arthritis, Rheumatoid 6Spondylitis, Ankylosing 2Psoriasis 2Crohn Disease 2Colitis, Ulcerative 2Uveal Melanoma 1Plaque Psoriasis 1Melanoma 1Hidradenitis Suppurativa 1Healthy Adult Male 1Healthy 1Acne Vulgaris 1Abscess 1

Interventions

pembrolizumab 7Ipilimumab 7Nivolumab 5Melphalan 5Dacarbazine 3tebentafusp 2sotrastaurin 2binimetinib 2Pemetrexed 2Crizotinib 2ADI PEG20 2utomilumab 1trametinib 1tocilizumab 1siremadlin 1ruxolitinib 1relatlimab 1obinutuzumab 1fludarabine phosphate 1fludarabine 1cemiplimab 1avelumab 1Watchful Waiting 1Toll-Like Receptor 1 1Standard of Care 1Solutions 1Rose Bengal 1Protein Kinase C 1Polyethylene Glycols 1Opdualag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uveal Melanoma × Adalimumab × Clear all
NCT04551352 2022-10-03

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Hoffmann-La Roche

Phase 1 Completed
20 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡